What went wrong in Connect Biopharma’s Seabreeze STAT asthma trial?
CNTB falls 32% after rademikibart misses its asthma primary endpoint despite a 66% treatment-failure reduction and significant FEV1 gain.
Pharma & Biotech
Pharma & Biotech
Can IBI3002 help Innovent Biologics challenge the next wave of type 2 inflammation therapies?
Bispecific antibodies are moving beyond oncology. Innovent’s autoimmune pipeline now faces the harder test of clinical durability.
Pharma & Biotech
What Transpire Bio’s Trelegy ANDA reveals about the next wave of inhaler competition
Trelegy is a blockbuster, but complex inhaler generics are closing in. Transpire Bio’s FDA filing could test GSK’s respiratory moat.
Medical Devices & Diagnostics
Why bioAffinity’s CyPath Lung growth still leaves investors facing a hard cash question
CyPath Lung is gaining clinical traction. The harder test is whether bioAffinity can scale adoption before cash pressure tightens.
Pharma & Biotech
Can Chance Pharma’s asthma inhaler challenge Symbicort’s grip on China’s respiratory market?
Asthma drugs are familiar. Delivery remains the problem. CXG87 could test whether better inhaler engineering changes China’s asthma market.
Pharma & Biotech
Cipla just cracked a $1.5bn U.S. inhaler market. Here’s why it matters
Find out how Cipla’s U.S. FDA approval for generic Ventolin HFA strengthens its respiratory portfolio and inhaler manufacturing strategy.
Pharma & Biotech
What AstraZeneca’s KALOS and LOGOS data reveal about triple inhaler therapy in asthma
AstraZeneca’s KALOS and LOGOS trials highlight triple inhaler therapy gains in asthma. Explore what this means for guidelines and payers.
Pharma & Biotech
GSK’s Trelegy Ellipta becomes China’s first approved triple therapy for both asthma and COPD
GSK plc has received regulatory approval from China’s National Medical Products Administration (NMPA) to market Trelegy Ellipta, a once-daily inhaled combination of fluticasone furoate, umeclidinium, and vilanterol, for the treatment of adult patients with uncontrolled asthma. This decision expands Trelegy Ellipta’s label beyond its existing indication in chronic obstructive pulmonary disease (COPD), making it the
Pharma & Biotech
Can Kinaset’s inhaled JAK inhibitor finally bring relief to all severe asthma patients?
Kinaset raises $103M to advance frevecitinib, a novel inhaled JAK inhibitor for severe asthma. Find out what makes this candidate different.
Pharma & Biotech
GSK strikes deal with U.S. to lower asthma and COPD drug prices and avoid tariffs
GSK plc’s latest agreement with the United States Administration to lower the price of respiratory medicines, including its inhaled asthma and chronic obstructive pulmonary disease (COPD) portfolio, signals a shift in how global pharmaceutical companies are choosing to respond to increasing U.S. political pressure around drug affordability. The agreement, announced on December 22, 2025, satisfies